Xu et al. [88] report that Prx6 is upregulated in cisplatin-resistant non-small-cell lung cancer (NSCLC) CSCs, and knocking it down lowers both CSC markers (CD133, ABCG2 (ATP-binding cassette subfamily G member 2)) and β-catenin levels. This evidence concerns the gene ABCG2 and non-small cell lung carcinoma.